GLAND PHARMA LIMITED Valuation

GLAND · Healthcare · Current price ₹2,867.9

Full stock page
DocStoX fair value
₹1,472
low confidence
Current price
₹2,868
Upside
-48.7%
P/E ratio
46.0x
P/B ratio
3.9x
Verdict
Avoid
Model it yourself — Earnings Yield Calculator
Opens pre-filled with GLAND PHARMA LIMITED's latest numbers.

Is GLAND PHARMA LIMITED undervalued?

DocStoX estimates the fair value of GLAND PHARMA LIMITED at ₹1,472 per share, versus the current market price of ₹2,868. That puts the stock about -48.7% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.

How this fair value is calculated

This estimate blends 4 independent methods: Residual income (₹608), Relative P/E (₹2,438), Graham floor (₹939), Analyst target (₹2,834). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.

Bear, base and bull scenarios

Our scenarios span ₹608 (bear) to ₹1,472 (base) to ₹2,834 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.

Valuation multiples

GLAND PHARMA LIMITED trades at a P/E of 46.0x and a P/B of 3.9x, with a dividend yield of 0.7%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.

Understand the ratios

P/E RatioP/B RatioPEG RatioEarnings Yield

More on GLAND PHARMA LIMITED

Fair ValueIntrinsic ValueDCFFinancial RatiosPeers

DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.